NewEdge Advisors’s Evoke Pharma EVOK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-17
Closed -$84 4268
2025
Q3
$84 Hold
17
﹤0.01% 4039
2025
Q2
$44 Hold
17
﹤0.01% 3933
2025
Q1
$47 Hold
17
﹤0.01% 3856
2024
Q4
$75 Hold
17
﹤0.01% 3801
2024
Q3
$81 Hold
17
﹤0.01% 3727
2024
Q2
$110 Hold
17
﹤0.01% 3684
2024
Q1
$127 Hold
17
﹤0.01% 3697
2023
Q4
$218 Hold
17
﹤0.01% 3600
2023
Q3
$287 Hold
17
﹤0.01% 3297
2023
Q2
$343 Hold
17
﹤0.01% 3346
2023
Q1
$395 Hold
17
﹤0.01% 3263
2022
Q4
$1 Buy
+17
New +$375 ﹤0.01% 4001

NewEdge Advisors's EVOK Position: Q4 2025 in Review

NewEdge Advisors sold out of Evoke Pharma (EVOK) in Q4 2025, closing a stake of 17 shares — an estimated $84 sold.

NewEdge Advisors first reported a position in EVOK in Q4 2022 and held it in 12 quarters. The position peaked at $395 in Q1 2023. 0 funds tracked by Wall St. Rank hold EVOK as of Q4 2025.

  • NewEdge Advisors reported no remaining Evoke Pharma position as of Q4 2025 after selling out during the quarter.
  • NewEdge Advisors sold 17 Evoke Pharma shares in Q4 2025, an estimated $84.
  • NewEdge Advisors first reported a position in Evoke Pharma in Q4 2022 and held it in 12 quarters.
  • NewEdge Advisors's Evoke Pharma position peaked at $395 in Q1 2023.
  • 0 funds tracked by Wall St. Rank held Evoke Pharma as of Q4 2025.

Based on NewEdge Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.